Report Detail
Global Companion Diagnostics (CDx) Development Services Market Research Report 2022
- RnM4444988 |
- 27 May, 2022 |
- Global |
- 103 Pages |
- QYResearch |
- Medical Devices & Consumables
Summary:
Industry Insights
The global Companion Diagnostics (CDx) Development Services market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Feasibility Studies accounting for % of the Companion Diagnostics (CDx) Development Services global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Infectious Diseases segment is altered to an % CAGR throughout this forecast period.
China Companion Diagnostics (CDx) Development Services market size is valued at US$ million in 2021, while the North America and Europe Companion Diagnostics (CDx) Development Services are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Companion Diagnostics (CDx) Development Services landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Companion Diagnostics (CDx) Development Services market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Companion Diagnostics (CDx) Development Services market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Companion Diagnostics (CDx) Development Services market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Companion Diagnostics (CDx) Development Services market.
Impact of Covid-19 Outbreak
This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.
Segmental Analysis
The report has been segmented into product and application segments. The researchers have documented all the products present today in the Companion Diagnostics (CDx) Development Services market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.
Companion Diagnostics (CDx) Development Services Breakdown Data by Type
Feasibility Studies
Assay Development
Analytical Validation
Clinical Validation
Others
Companion Diagnostics (CDx) Development Services Breakdown Data by Application
Infectious Diseases
Neurological Disorders
Regional Analysis
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Competitive Landscape
This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:
Geneuity-Clinical Research Services
Interpace Biosciences
Labcorp
Quest Diagnostics
Q² Solutions
ResearchDx
Almac Diagnostic Services
Biocartis
Cerba Research
Eurofins Scientific
MLM Medical Labs
Qiagen
BGI Genomics
MEDx Translational Medicine
Medical Biological Laboratories (MBL)
Novogene
Frequently Asked Questions
What factors will challenge the Companion Diagnostics (CDx) Development Services market growth?
Which end-use segment will expand at the fastest CAGR in the Companion Diagnostics (CDx) Development Services market?
Which are the emerging players in the Companion Diagnostics (CDx) Development Services market?
How concentrated is the Companion Diagnostics (CDx) Development Services market?
Which factors are positively contributing to the Companion Diagnostics (CDx) Development Services market growth?
Which are the novel product innovations in the Companion Diagnostics (CDx) Development Services market?
Which product segment will emerge as the most lucrative in the Companion Diagnostics (CDx) Development Services market?
Which factors are increasing the competition in the Companion Diagnostics (CDx) Development Services market?
Which are the strategic measures taken by the Companion Diagnostics (CDx) Development Services industry players?
Which region will witness inactive growth during the forecast period?
What key trends are likely to emerge in the Companion Diagnostics (CDx) Development Services market in the coming years?
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global Companion Diagnostics (CDx) Development Services Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
- 1.2.2 Feasibility Studies
- 1.2.3 Assay Development
- 1.2.4 Analytical Validation
- 1.2.5 Clinical Validation
- 1.2.6 Others
- 1.3 Market by Application
- 1.3.1 Global Companion Diagnostics (CDx) Development Services Market Share by Application: 2017 VS 2021 VS 2028
- 1.3.2 Infectious Diseases
- 1.3.3 Neurological Disorders
- 1.4 Study Objectives
- 1.5 Years Considered
2 Global Growth Trends
- 2.1 Global Companion Diagnostics (CDx) Development Services Market Perspective (2017-2028)
- 2.2 Companion Diagnostics (CDx) Development Services Growth Trends by Region
- 2.2.1 Companion Diagnostics (CDx) Development Services Market Size by Region: 2017 VS 2021 VS 2028
- 2.2.2 Companion Diagnostics (CDx) Development Services Historic Market Size by Region (2017-2022)
- 2.2.3 Companion Diagnostics (CDx) Development Services Forecasted Market Size by Region (2023-2028)
- 2.3 Companion Diagnostics (CDx) Development Services Market Dynamics
- 2.3.1 Companion Diagnostics (CDx) Development Services Industry Trends
- 2.3.2 Companion Diagnostics (CDx) Development Services Market Drivers
- 2.3.3 Companion Diagnostics (CDx) Development Services Market Challenges
- 2.3.4 Companion Diagnostics (CDx) Development Services Market Restraints
3 Competition Landscape by Key Players
- 3.1 Global Top Companion Diagnostics (CDx) Development Services Players by Revenue
- 3.1.1 Global Top Companion Diagnostics (CDx) Development Services Players by Revenue (2017-2022)
- 3.1.2 Global Companion Diagnostics (CDx) Development Services Revenue Market Share by Players (2017-2022)
- 3.2 Global Companion Diagnostics (CDx) Development Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.3 Players Covered: Ranking by Companion Diagnostics (CDx) Development Services Revenue
- 3.4 Global Companion Diagnostics (CDx) Development Services Market Concentration Ratio
- 3.4.1 Global Companion Diagnostics (CDx) Development Services Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Top 10 and Top 5 Companies by Companion Diagnostics (CDx) Development Services Revenue in 2021
- 3.5 Companion Diagnostics (CDx) Development Services Key Players Head office and Area Served
- 3.6 Key Players Companion Diagnostics (CDx) Development Services Product Solution and Service
- 3.7 Date of Enter into Companion Diagnostics (CDx) Development Services Market
- 3.8 Mergers & Acquisitions, Expansion Plans
4 Companion Diagnostics (CDx) Development Services Breakdown Data by Type
- 4.1 Global Companion Diagnostics (CDx) Development Services Historic Market Size by Type (2017-2022)
- 4.2 Global Companion Diagnostics (CDx) Development Services Forecasted Market Size by Type (2023-2028)
5 Companion Diagnostics (CDx) Development Services Breakdown Data by Application
- 5.1 Global Companion Diagnostics (CDx) Development Services Historic Market Size by Application (2017-2022)
- 5.2 Global Companion Diagnostics (CDx) Development Services Forecasted Market Size by Application (2023-2028)
6 North America
- 6.1 North America Companion Diagnostics (CDx) Development Services Market Size (2017-2028)
- 6.2 North America Companion Diagnostics (CDx) Development Services Market Size by Country (2017-2022)
- 6.3 North America Companion Diagnostics (CDx) Development Services Market Size by Country (2023-2028)
- 6.4 United States
- 6.5 Canada
7 Europe
- 7.1 Europe Companion Diagnostics (CDx) Development Services Market Size (2017-2028)
- 7.2 Europe Companion Diagnostics (CDx) Development Services Market Size by Country (2017-2022)
- 7.3 Europe Companion Diagnostics (CDx) Development Services Market Size by Country (2023-2028)
- 7.4 Germany
- 7.5 France
- 7.6 U.K.
- 7.7 Italy
- 7.8 Russia
- 7.9 Nordic Countries
8 Asia-Pacific
- 8.1 Asia-Pacific Companion Diagnostics (CDx) Development Services Market Size (2017-2028)
- 8.2 Asia-Pacific Companion Diagnostics (CDx) Development Services Market Size by Country (2017-2022)
- 8.3 Asia-Pacific Companion Diagnostics (CDx) Development Services Market Size by Country (2023-2028)
- 8.4 China
- 8.5 Japan
- 8.6 South Korea
- 8.7 Southeast Asia
- 8.8 India
- 8.9 Australia
9 Latin America
- 9.1 Latin America Companion Diagnostics (CDx) Development Services Market Size (2017-2028)
- 9.2 Latin America Companion Diagnostics (CDx) Development Services Market Size by Country (2017-2022)
- 9.3 Latin America Companion Diagnostics (CDx) Development Services Market Size by Country (2023-2028)
- 9.4 Mexico
- 9.5 Brazil
10 Middle East & Africa
- 10.1 Middle East & Africa Companion Diagnostics (CDx) Development Services Market Size (2017-2028)
- 10.2 Middle East & Africa Companion Diagnostics (CDx) Development Services Market Size by Country (2017-2022)
- 10.3 Middle East & Africa Companion Diagnostics (CDx) Development Services Market Size by Country (2023-2028)
- 10.4 Turkey
- 10.5 Saudi Arabia
- 10.6 UAE
11 Key Players Profiles
- 11.1 Geneuity-Clinical Research Services
- 11.1.1 Geneuity-Clinical Research Services Company Detail
- 11.1.2 Geneuity-Clinical Research Services Business Overview
- 11.1.3 Geneuity-Clinical Research Services Companion Diagnostics (CDx) Development Services Introduction
- 11.1.4 Geneuity-Clinical Research Services Revenue in Companion Diagnostics (CDx) Development Services Business (2017-2022)
- 11.1.5 Geneuity-Clinical Research Services Recent Development
- 11.2 Interpace Biosciences
- 11.2.1 Interpace Biosciences Company Detail
- 11.2.2 Interpace Biosciences Business Overview
- 11.2.3 Interpace Biosciences Companion Diagnostics (CDx) Development Services Introduction
- 11.2.4 Interpace Biosciences Revenue in Companion Diagnostics (CDx) Development Services Business (2017-2022)
- 11.2.5 Interpace Biosciences Recent Development
- 11.3 Labcorp
- 11.3.1 Labcorp Company Detail
- 11.3.2 Labcorp Business Overview
- 11.3.3 Labcorp Companion Diagnostics (CDx) Development Services Introduction
- 11.3.4 Labcorp Revenue in Companion Diagnostics (CDx) Development Services Business (2017-2022)
- 11.3.5 Labcorp Recent Development
- 11.4 Quest Diagnostics
- 11.4.1 Quest Diagnostics Company Detail
- 11.4.2 Quest Diagnostics Business Overview
- 11.4.3 Quest Diagnostics Companion Diagnostics (CDx) Development Services Introduction
- 11.4.4 Quest Diagnostics Revenue in Companion Diagnostics (CDx) Development Services Business (2017-2022)
- 11.4.5 Quest Diagnostics Recent Development
- 11.5 Q² Solutions
- 11.5.1 Q² Solutions Company Detail
- 11.5.2 Q² Solutions Business Overview
- 11.5.3 Q² Solutions Companion Diagnostics (CDx) Development Services Introduction
- 11.5.4 Q² Solutions Revenue in Companion Diagnostics (CDx) Development Services Business (2017-2022)
- 11.5.5 Q² Solutions Recent Development
- 11.6 ResearchDx
- 11.6.1 ResearchDx Company Detail
- 11.6.2 ResearchDx Business Overview
- 11.6.3 ResearchDx Companion Diagnostics (CDx) Development Services Introduction
- 11.6.4 ResearchDx Revenue in Companion Diagnostics (CDx) Development Services Business (2017-2022)
- 11.6.5 ResearchDx Recent Development
- 11.7 Almac Diagnostic Services
- 11.7.1 Almac Diagnostic Services Company Detail
- 11.7.2 Almac Diagnostic Services Business Overview
- 11.7.3 Almac Diagnostic Services Companion Diagnostics (CDx) Development Services Introduction
- 11.7.4 Almac Diagnostic Services Revenue in Companion Diagnostics (CDx) Development Services Business (2017-2022)
- 11.7.5 Almac Diagnostic Services Recent Development
- 11.8 Biocartis
- 11.8.1 Biocartis Company Detail
- 11.8.2 Biocartis Business Overview
- 11.8.3 Biocartis Companion Diagnostics (CDx) Development Services Introduction
- 11.8.4 Biocartis Revenue in Companion Diagnostics (CDx) Development Services Business (2017-2022)
- 11.8.5 Biocartis Recent Development
- 11.9 Cerba Research
- 11.9.1 Cerba Research Company Detail
- 11.9.2 Cerba Research Business Overview
- 11.9.3 Cerba Research Companion Diagnostics (CDx) Development Services Introduction
- 11.9.4 Cerba Research Revenue in Companion Diagnostics (CDx) Development Services Business (2017-2022)
- 11.9.5 Cerba Research Recent Development
- 11.10 Eurofins Scientific
- 11.10.1 Eurofins Scientific Company Detail
- 11.10.2 Eurofins Scientific Business Overview
- 11.10.3 Eurofins Scientific Companion Diagnostics (CDx) Development Services Introduction
- 11.10.4 Eurofins Scientific Revenue in Companion Diagnostics (CDx) Development Services Business (2017-2022)
- 11.10.5 Eurofins Scientific Recent Development
- 11.11 MLM Medical Labs
- 11.11.1 MLM Medical Labs Company Detail
- 11.11.2 MLM Medical Labs Business Overview
- 11.11.3 MLM Medical Labs Companion Diagnostics (CDx) Development Services Introduction
- 11.11.4 MLM Medical Labs Revenue in Companion Diagnostics (CDx) Development Services Business (2017-2022)
- 11.11.5 MLM Medical Labs Recent Development
- 11.12 Qiagen
- 11.12.1 Qiagen Company Detail
- 11.12.2 Qiagen Business Overview
- 11.12.3 Qiagen Companion Diagnostics (CDx) Development Services Introduction
- 11.12.4 Qiagen Revenue in Companion Diagnostics (CDx) Development Services Business (2017-2022)
- 11.12.5 Qiagen Recent Development
- 11.13 BGI Genomics
- 11.13.1 BGI Genomics Company Detail
- 11.13.2 BGI Genomics Business Overview
- 11.13.3 BGI Genomics Companion Diagnostics (CDx) Development Services Introduction
- 11.13.4 BGI Genomics Revenue in Companion Diagnostics (CDx) Development Services Business (2017-2022)
- 11.13.5 BGI Genomics Recent Development
- 11.14 MEDx Translational Medicine
- 11.14.1 MEDx Translational Medicine Company Detail
- 11.14.2 MEDx Translational Medicine Business Overview
- 11.14.3 MEDx Translational Medicine Companion Diagnostics (CDx) Development Services Introduction
- 11.14.4 MEDx Translational Medicine Revenue in Companion Diagnostics (CDx) Development Services Business (2017-2022)
- 11.14.5 MEDx Translational Medicine Recent Development
- 11.15 Medical Biological Laboratories (MBL)
- 11.15.1 Medical Biological Laboratories (MBL) Company Detail
- 11.15.2 Medical Biological Laboratories (MBL) Business Overview
- 11.15.3 Medical Biological Laboratories (MBL) Companion Diagnostics (CDx) Development Services Introduction
- 11.15.4 Medical Biological Laboratories (MBL) Revenue in Companion Diagnostics (CDx) Development Services Business (2017-2022)
- 11.15.5 Medical Biological Laboratories (MBL) Recent Development
- 11.16 Novogene
- 11.16.1 Novogene Company Detail
- 11.16.2 Novogene Business Overview
- 11.16.3 Novogene Companion Diagnostics (CDx) Development Services Introduction
- 11.16.4 Novogene Revenue in Companion Diagnostics (CDx) Development Services Business (2017-2022)
- 11.16.5 Novogene Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
- 13.1 Research Methodology
- 13.1.1 Methodology/Research Approach
- 13.1.2 Data Source
- 13.2 Disclaimer
Summary:
Get latest Market Research Reports on Companion Diagnostics (CDx) Development Services. Industry analysis & Market Report on Companion Diagnostics (CDx) Development Services is a syndicated market report, published as Global Companion Diagnostics (CDx) Development Services Market Research Report 2022. It is complete Research Study and Industry Analysis of Companion Diagnostics (CDx) Development Services market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
